Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 05 July 2017 | By Zachary Brennan
The US Department of Health and Human Services’ Office of Inspector General (OIG) warns that "systemic issues" with the Centers for Disease Control and Prevention’s (CDC) stockpile of vaccines, antibiotics, antidotes, antitoxins, medications and other supplies could place at risk approximately $7 billion of inventory and negatively affect readiness during a national emergency.
Created in 1999, the stockpile is meant to supplement and resupply state and local public health agencies in the event of a national emergency.
OIG audits from 2005 found that stockpile sites lacked adequate protection against theft, tampering, destruction or other loss. And though more recent audits of five selected stockpile sites confirmed that inventory was adequately protected, OIG said in a report issued recently that "some issues" within the inventory system could present risks if CDC does not take corrective action.
OIG’s report found, "Two primary systemic issues may prevent CDC from ensuring that Stockpile sites are adequately protected and that inventory is readily deployable in a public health emergency: although no longer responsible for providing Stockpile security, the Division of Strategic National Stockpile (DSNS) still controls security funding, and the Stockpile automated inventory system did not always accurately track the movement of all inventory or accurately record inventory locations."
Part of the problem, according to OIG, is that in 2005, CDC transferred the responsibility for physical security protection of the stockpile from DSNS to its Office of Safety, Security, and Asset Management (OSSAM), but it did not transfer security funding to OSSAM.
And the automated inventory system did not always accurately manage inventory because DSNS has not taken steps to ensure that the system has the necessary capabilities to do so. OIG recommends that CDC (1) consider directly funding OSSAM's stockpile security mission and (2) improve its automated inventory system so that it can accurately identify inventory movements and locations at all times.
CDC concurred with OIG’s recommendations and described steps that it had taken or planned to take to address them.
OIG
Tags: CDC, stockpile of medical products, vaccines, DSNS, OSSAM
Regulatory Focus newsletters
All the biggest regulatory news and happenings.